[1]Doty RL. Olfaction in Parkinson’s disease and related disorders[J]. Neurobiol Dis, 2012, 46(3): 527-552.
[2]Wallace VC, Chaudhuri KR. Unexplained lower limb pain in Parkinson’s disease: a phenotypic variant of “painful Parkinson’s disease”[J]. Parkinsonism Related Disord, 2014,20(1):122-124.
[3]Neikrug AB, Maglione JE, Liu L,et al. Effects of sleep disorders on the non-motor symptoms of Parkinson disease[J].J Clin Sleep Med,2013,9(11):1119-1129.
[4]Brodoehl S, Klingner C, Volk GF, et al. Decreased olfactory bulb volume in idiopathic Parkinson’s disease detected by 3.0-Tesla magnetic resonance imaging[J]. Mov Disord, 2012, 27(8): 1019-1025.
[5]Haehner A, Boesveldt S, Berendse HW. et al. Prevalence of smell loss in Parkinson’s disease-a multicenter study[J]. Parkinsonism Relat Disord, 2009, 15(7): 490-494.
[6]Belzunegui S, Sebastián W, Garrido-Gil P, et al. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP[J]. Synapse, 2007, 61(12): 1006-1012.
[7]Bundschuh ST, Zhu P, Schrer YP, et al. Dopaminergic modulation of mitral cells and odor responses in the zebrafish olfactory bulb[J]. J Neurosci, 2012, 32(20): 6830-6840.
[8]Cave J W, Baker H. Dopamine Systems in the Forebrain. Development and Engineering of Dopamine Neurons [M]. New York: Springer, 2009: 15-35.
[9]Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson’s disease: possible implications for early diagnosis[J]. Mov Disord, 2001; 16(1): 41-46.
[10]Huisman E, Uyings HB, Hoogland PV. A 100% increase of dopaminergic in Parkinson’s disease[J]. Mov Disord, 2004, 19(6): 687-692.
[11]Herring B, Shchulze S, Reichman H, et al. A longitudinal study of olfactory function in patients with idiopathic Parkinson’s diease[J]. J Neurol, 2008, 255(3): 367-370.
[12]H?kfelt T, Halasz N, Ljungdahl ?, et al. Histochemical support for a dopaminergic mechanism in the dendrites of certain periglomerular cells in the rat olfactory bulb [J]. Neurosci Lett, 1975, 1(2): 85-90.
[13]Yuste JE, Echeverry MB, Ros-Bernal F, et al. 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson’s disease[J]. Neuropharmacology, 2012,63(7): 1258-1267.
[14]Brown AM, Baucum AJ, Bass MA, et al. Association of protein phosphatase 1 gamma 1 with spinophilin suppresses phosphatase activity in a Parkinson disease model[J]. J Biol Chem, 2008, 283(21): 14286-14294. |